As September comes to a close, it’s time to welcome the best season of the year—fall. Moving away from the blistering heat of the summer, we have now entered the season of changing leaves, temperatures dipping and pumpkin spice returning the market. But the weather isn't the only thing that's shifting: Boston businesses also went through a number of changes and handovers last month.
During September, there were a number of mergers and acquisitions, including the purchase of Peabody-based BK Medical by General Electric Co.'s health care division for $1.45 billion. Scroll through the rest below to see highlights of local M&A news.
Stay on top of who's getting acquired by signing up for The Beat right here. See you in your inbox!
Here are the highlights from September 2021:
New Jersey-based Merck has agreed to pay $11.5 billion in cash for Cambridge-based Acceleron, valuing each share at $180 each.
Boston-based OpenExchange, which offers virtual conferencing for the financial services sector, has acquired Nucleus195, which developed an online for independent investment research. The acquisition comes after OpenExchange raised $23M in Series D preferred stock.
Sovos, a Wilmington-based company that makes tax preparer software, has acquired California-based tax software company 1099 Pro. Sovos said the acquisition broadens its tax offerings for small- and medium-sized businesses. Details of the deal were not disclosed.
Fenix Parent LLC, a Texas-based company that recycles and resells automotive parts, has acquired the assets of Winchendon-based automotive recycling facility New England Auto & Truck Recyclers. Terms of the acquisition were not disclosed.
Boston-based Desktop Metal Inc. has acquired Aidro, an Italy-based maker of valves, manifolds and other hydraulic- and fluid-power systems. Terms of the deal were not disclosed. The acquisition is expected to help Desktop Metal speed up adoption of additive manufacturing sales in such industries as oil and gas, aerospace, machining and more.
Creation Technologies, a Boston-based electronic manufacturing services provider, has acquired Idaho-based Computrol Inc. The acquisition means Creation will add locations in Meridian, Idaho and Westminster, Colorado, adding a combined 100,000 square feet of production space. Terms of the deal were not disclosed.
Prime Automotive, which has 30 dealerships in the Northeast, has been acquired by Houston-based Group 1 Automotive.
Medical device maker Zoll Medical Corp. is acquiring Itamar Medical Ltd. in a deal valued at $538M. Chelmsford-based Zoll plans to acquire all outstanding shares of Israel–based Itamar, which makes sleep apnea and other sleep-disorder devices.
Needham-based Syniti, which helps companies manage their data, has acquired Austin, Texas-based 360Science. Syniti plans to integrate 360Science’s matchit software into the company’s knowledge platform to bolster the product. Terms of the deal were not disclosed.
Zappi, a Boston-based ad testing platform for brands, has acquired Chicago-based startup Data Quorum. The acquisition gives Zappi access to the startup's library of statistical tools. Terms were not disclosed.
Park Place Technologies, an IT infrastructure services and solutions provider, announced the acquisition of specific assets of Norwell-based Congruity360, a provider of IT management services.
WillowTree, a digital product consultancy, announced the acquisition of Maark, a Boston-based digital transformation agency specializing in Adobe Experience Cloud.
Akamai Technologies Inc., the Cambridge-based Internet giant, said it is acquiring Tel Aviv, Israel-based Guardicore for about $600 million in a deal expected to close in the fourth quarter of 2021.
General Electric Co.'s health care division has agreed to pay $1.45 billion to acquire BK Medical, a Peabody-based maker of tools that assist surgeons during invasive and robotic operations.
The maker of cannabis-infused seltzer brand Levia has been acquired by Ayr Wellness in a deal that could reach as much as $60 million, bringing the local brand into a multistate cannabis company. Georgetown-based Cultivauna LLC, which owns Levia, announced that it has signed a deal in which Ayr would acquire 100% of the equity of the company for $20 million in cash and stock, and up to $40 million in additional earnouts based on revenue over the next two years. The acquisition is expected to close by the end of the year.
Boston Scientific Corp. is shelling out as much as $336 million to acquire the remainder of medical device firm Devoro Medical, which it has held a stake in since 2019. The payment consists of $269 million paid up front for the 84% of the company Boston Scientific does not already own, plus up to $67 million in possible milestone payments.
Boston Scientific said it has also closed a deal exceeding $1 billion for the surgical business of the laser firm Lumenis.
Threat Stack, a Boston-based cloud security and workload protection provider, is getting acquired in a deal worth $68 million. Seattle-based F5 Networks Inc., a multi-cloud application security and delivery company with a market capitalization of $12.17 billion, said it plans to buy Threat Stack to help customers adopt consistent security in any cloud. F5 plans to acquire all issued and outstanding shares of Threat Stack for $68 million in cash. The deal is expected to close by the end of 2021.
Waltham drug developer Repligen is paying $150 million in cash and stock to acquire a New Hampshire-based chromatography developer called Avitide Inc. Repligen is spending $75 million cash and another $75 million in stock for the company.
Sanofi S.A. is buying biopharmaceutical company Kadmon Holdings Inc. for $1.9 billion. Kadmon is headquartered in New York with an office in Cambridge.
EnBiotix Inc., a Boston-based biotech focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. Under the terms of the agreement, Polyphor will acquire all of EnBiotix's outstanding capital stock; EnBiotix will in turn acquire the rights to inhaled murepavadin, a potent antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in cystic fibrosis patients, for $10 million. The merger is expected to close in the fourth quarter of this year.
